141 related articles for article (PubMed ID: 38775250)
1. Influence of cachexia on immunotherapy efficacy and prognosis for malignant tumors of the digestive system.
Tao Z; Chen Z; Gao Y; Quan M
Cancer Rep (Hoboken); 2024 May; 7(5):e2100. PubMed ID: 38775250
[TBL] [Abstract][Full Text] [Related]
2. [The influence of cachexia on the immunotherapy efficacy of Sintilimab for non-small cell lung cancer].
Li XQ; Zhao ZL; Hou ML; Cui YX; Han SY; Fu FF
Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1292-1297. PubMed ID: 34915639
[No Abstract] [Full Text] [Related]
3. Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancer.
Miyawaki T; Naito T; Doshita K; Kodama H; Mori M; Nishioka N; Iida Y; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Ko R; Wakuda K; Ono A; Kenmotsu H; Murakami H; Mori K; Harada H; Endo M; Takahashi K; Takahashi T
Thorac Cancer; 2022 Jul; 13(14):2064-2074. PubMed ID: 35698259
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of the cachexia index in patients with small cell lung cancer.
Go SI; Park MJ; Lee GW
BMC Cancer; 2021 May; 21(1):563. PubMed ID: 34001060
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab.
Jo H; Yoshida T; Horinouchi H; Yagishita S; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Yamamoto N; Takahashi K; Motoi N; Ohe Y
Cancer Immunol Immunother; 2022 Feb; 71(2):387-398. PubMed ID: 34180007
[TBL] [Abstract][Full Text] [Related]
6. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.
Roch B; Coffy A; Jean-Baptiste S; Palaysi E; Daures JP; Pujol JL; Bommart S
Lung Cancer; 2020 May; 143():19-26. PubMed ID: 32200137
[TBL] [Abstract][Full Text] [Related]
7. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer.
Demirelli B; Babacan NA; Ercelep Ö; Öztürk MA; Kaya S; Tanrıkulu E; Khalil S; Hasanov R; Alan Ö; Telli TA; Koca S; Arıbal ME; Kuzan B; Dane F; Yumuk PF
Nutr Cancer; 2021; 73(2):230-238. PubMed ID: 32270713
[No Abstract] [Full Text] [Related]
8. Hand grip strength-based cachexia index as a predictor of cancer cachexia and prognosis in patients with cancer.
Xie H; Ruan G; Wei L; Zhang H; Ge Y; Zhang Q; Lin S; Song M; Zhang X; Liu X; Li X; Zhang K; Yang M; Tang M; Song CH; Gan J; Shi HP
J Cachexia Sarcopenia Muscle; 2023 Feb; 14(1):382-390. PubMed ID: 36447437
[TBL] [Abstract][Full Text] [Related]
9. In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer.
Wang H; Nie C; Xu W; Li J; Gou H; Lv H; Chen B; Wang J; Liu Y; He Y; Zhao J; Chen X
Therap Adv Gastroenterol; 2024; 17():17562848241245455. PubMed ID: 38617123
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of the combination of body composition and systemic inflammation in patients with cancer cachexia.
Xie HL; Ruan GT; Wei L; Zhang Q; Ge YZ; Song MM; Zhang X; Lin SQ; Liu XY; Zhang XW; Li XR; Zhang KP; Hu CL; Yang M; Tang M; Song CH; Cong MH; Weng M; Li ZN; Li W; Wang KH; Shi HP
J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):879-890. PubMed ID: 36872512
[TBL] [Abstract][Full Text] [Related]
11. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive evaluation of serum hepatic proteins in predicting prognosis among cancer patients with cachexia: an observational cohort study.
Huang JX; Zhang X; Tang M; Zhang Q; Deng L; Song CH; Li W; Shi HP; Cong MH
BMC Cancer; 2024 Mar; 24(1):293. PubMed ID: 38438901
[TBL] [Abstract][Full Text] [Related]
13. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a cancer cachexia risk score for digestive tract cancer patients before abdominal surgery.
Tan S; Xu J; Wang J; Zhang Z; Li S; Yan M; Tang M; Liu H; Zhuang Q; Xi Q; Meng Q; Jiang Y; Wu G
J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):891-902. PubMed ID: 36880286
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy.
Goh MJ; Kang W; Jeong WK; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Sci Rep; 2022 May; 12(1):7647. PubMed ID: 35538112
[TBL] [Abstract][Full Text] [Related]
16. Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Matsuo N; Azuma K; Murotani K; Murata D; Matama G; Kawahara A; Kojima T; Tokito T; Hoshino T
Thorac Cancer; 2023 May; 14(15):1362-1367. PubMed ID: 37037511
[TBL] [Abstract][Full Text] [Related]
17. Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study.
Kim SH; Lee DE; Joung JY; Seo HK; Lee KH; Chung J
Investig Clin Urol; 2020 Mar; 61(2):146-157. PubMed ID: 32158965
[TBL] [Abstract][Full Text] [Related]
18. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
19. Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large B-cell lymphoma.
Go SI; Park MJ; Park S; Kang MH; Kim HG; Kang JH; Kim JH; Lee GW
J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):2211-2219. PubMed ID: 34676685
[TBL] [Abstract][Full Text] [Related]
20. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Santoni M; Buti S; Myint ZW; Maruzzo M; Iacovelli R; Pichler M; Kopecky J; Kucharz J; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Kopp RM; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Massari F; Seront E; Calabrò F; Pinto A; Berardi R; Zgura A; Mammone G; Ansari J; Atzori F; Chiari R; Bamias A; Caffo O; Procopio G; Sunela K; Bassanelli M; Ortega C; Grillone F; Landmesser J; Milella M; Messina C; Küronya Z; Mosca A; Bhuva D; Santini D; Vau N; Morelli F; Incorvaia L; Rebuzzi SE; Roviello G; Soares A; Bisonni R; Bimbatti D; Zabalza IO; Rizzo A; Mollica V; Sorgentoni G; Monteiro FSM; Battelli N; Bracarda S; Porta C
Eur Urol Oncol; 2024 Feb; 7(1):102-111. PubMed ID: 37481365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
